Kornimate/medical-research-clean huggingface dataset:
effects of core strengthening versus motor control training on pain, disability & endurance in low back pain

Conditions: Low Back Pain

Summary: the study aims to compare the effects of core strengthening versus motor control training on pain, disability \& endurance in patients with low back pain

the study aims to compare the effects of core strengthening versus motor control training on pain, disability \& endurance in patients with low back pain. comparing core strength and conditioning versus motor control for low back pain on physical and self-report outcomes lies in identifying the most effective treatment approach for this condition. this will help to determine which one yields better results in terms of improving physical function and reducing self-reported pain and disability associated with low back pain. this study can provide valuable insights for clinicians and patients in selecting the most appropriate treatment option.

Eligibility criteria:
inclusion criteria: * non-specific chronic low back pain (\>3 months) * pain between the t12 vertebra and gluteal fold with pain of 2-8 on the numerical rating scale of 0-10 * both genders * age of 25 and above exclusion criteria: * participants fall in this category would be excluded of the study. * lumbar radiculopathy * structural scoliosis * traumatic spinal injury * cauda equina syndrome * history of seizures, epilepsy, stroke or head injury * metal implants * pregnancy or considering pregnancy in near future * body mass \>/= 100kg

Keywords: back pain disability endurance core strengthening motor control
does intra-operative marginprobe use reduce re-excision rates?

Conditions: Breast Cancer

Summary: the new device we are looking at is called the marginprobe. it is a disposable probe which measures the margins of tissue removed to check they are clear of cancer cells, during breast conservation surgery. after specimen radiology, allows the surgeon to remove further tissue if necessary, during the same operation if any involved margins are identified. this minimises the need for further repeat operations. previous studies carried out elsewhere in the world (usa and israel) have identified that the probe reduces re-excision rate but there has never been a study in the uk. the trial involves randomly allocating patients once they are in theatre, to either the marginprobe procedure after breast conserving surgery and radiology has been completed, or not.

almost 60% of all patients diagnosed with breast cancer (48000 annually in the uk) undergo breast conserving surgery (bcs. surgical removal of the cancer aims to reduce the risk of local recurrence and patient mortality. in order to minimise the amount of tissue removed, excision up to the cancer-free area (margins) is undertaken. further surgery, following initial breast cancer surgery, is required in 25% - 30% of patients because of disease found at the edges of the tissue removed. reducing the need for further operations benefits patients (by reducing the number of operations required, improving cosmetic outcome and minimising anxiety) and the nhs (by realising economic benefits). marginprobe, a disposable probe which measures the margins of tissue removed during breast cancer surgery, allows the surgeon to remove further tissue during the same surgical procedure to clear any involved margins, minimising subsequent re-operations. four hundred and sixty patients in 6 specialist breast units will be randomly allocated after bcs (and specimen radiology), by telephone randomisation, to either: * marginprobe assessment of the surgical specimen with re-excision of margins if required; * standard bcs (clinical and radiological clear margins) whereby the wound will be closed and the surgery completed (standard uk practice).

Eligibility criteria:
inclusion criteria; * women aged 18-90 years with dcis or invasive breast cancer containing dcis diagnosed histopathologically. * histologically diagnosed dcis or invasive lobular cancer in core biopsy (b5a or b5b). * tumour size 1.5cm - 4cm and undergoing breast cancer surgery. written informed consent. exclusion criteria; * unsuitable for bcs on basis of tumour size (\ 4cm) or stage. * radiotherapy contraindicated. * no histopathological evidence of dcis or invasive lobular cancer. * neoadjuvant chemotherapy.
the correlations of feno, blood eosinophils and lung function in well-controlled asthma

Conditions: Asthma

Summary: in asthma, the levels of exhaled feno is correlated to sputum eosinophils particularly in the patient with poor controlled asthma or severe asthma. moreover, the blood eosinophils had been studied that are also correlated to sputum eosinophils in similar patients group. according to well controlled asthma, althoug hin clinical practice guidelines recommend that the stepping down therapy should be considered to those patients due to the risks or costs of daily treatment, there is previous study has been shown that the airway hyperresponsiveness and sputum eosinophilia are predictors of loss of control during dose reduction. and, these tests are not readily available in primary care. however, there is limit number of clinical study to study the correlation of biologic markers among the patients with well controlled level before the stepping down management.

this is a single prospective trial. enrollment will continue until 50 patients with well controlled asthma have been entered into this trial and have completed blood tests and spirometry. in this trial, the following parameters are to be evaluated: blood eosinophils (absolute and relative) feno pulmonary lung function test: fev1, fvc, pf, mmef 25-75%, % reversibility

Eligibility criteria:
inclusion criteria: * patients with diagnosis of asthma (according to the guidelines) * age \>15 years * patients with treating with step 3 base on gina by only low dose ics/laba without oral bronchodilator with being in well controlled asthma based on act (\> = 23) and acq-7 (\<0.75) for at least 12 weeks * ability to provide informed consent and do spirometry following ats guideline exclusion criteria: * pulmonary infection or exacerbation within the last 12 weeks before enrolment * patients with preceding taken systemic steroid 12 week before enrolment * additional pulmonary diseases (pneumonia, lung cancer, tuberculosis, interstitial lung disease) * a history of smoking \>= 10 pack-year

Keywords: feno blood eosinophil pulmonary function test well controlled asthma
efficacy and safety of inhaled isoflurane delivered via the sedaconda acd-s compared to intravenous propofol for sedation of mechanically ventilated intensive care unit adult patients (inspire-icu1)

Conditions: Sedation

Summary: this is a study to compare safety and efficacy of inhaled isoflurane administered via the sedaconda acd-s device system versus intravenous propofol for sedation of mechanically ventilated patients in the intensive care unit (icu) setting.

this is a phase 3, multicenter, randomized, controlled, open-label, assessor-blinded study to evaluate the efficacy and safety of inhaled isoflurane delivered via the sedaconda acd-s compared to intravenous propofol for sedation of mechanically ventilated intensive care unit (icu) adult patients.

Eligibility criteria:
inclusion criteria: * adults ≥18 years of age; * patients who are anticipated to require \>12 hours of invasive mechanical ventilation and continuous sedation in the icu; and * receipt of continuous sedation due to clinical need for sedation to rass \<0. exclusion criteria: * need for rass -5; * sedation for invasive mechanical ventilation immediately prior to baseline for \>72 hours; * severe neurological condition before icu admission that causes the patient to lack ability to participate in the study (ie, unable to be assessed for rass and cpot); * ventilator tidal volume \ 1000 ml at baseline; * need for extracorporeal membrane oxygenation (ecmo), extracorporeal co2 removal (ecco2r), high frequency oscillation ventilation (hfov), or high frequency percussive ventilation (hfpv) at screening; * comfort care only (end of life care); * contraindication to propofol or isoflurane; * known or family history of mh; * severe hemodynamic compromise, defined as the need for norepinephrine ≥0.3 mcg/kg/min (or equivalent vasopressor dose) to maintain blood pressure within acceptable range, assumed to be mean arterial pressure ≥65 mmhg unless prescribed clinically; * allergy to isoflurane or propofol, or have propofol infusion syndrome. * history of ventricular tachycardia/long qt syndrome; * requirement of iv benzodiazepine or barbiturate administration for seizures or dependencies, including alcohol withdrawal * neuromuscular disease that impairs spontaneous ventilation (eg, c5 or higher spinal cord injury, amyotrophic lateral sclerosis, etc); * concurrent enrollment in another study that, in the investigator's opinion, would impact the patient's safety or assessments of this study; * participation in other study involving investigational drug(s) or devices(s) within 30 days prior to randomization; * anticipated requirement of treatment with continuous infusion of a neuromuscular blocking agent for \>4 hours; * female patients who are pregnant or breast-feeding; * imperative need for continuous active humidification through mechanical ventilation circuit; * attending physician's refusal to include the patient; or * inability to obtain informed consent.

Keywords: sedation mechanical ventilation isoflurane propofol icu
comparison of effect-site concentration of remifentanil for preventing cough against endotracheal tube during anesthetic emergence according to anesthetics (sevoflurane, desflurane, and propofol)

Conditions: Female Patients Undergoing Thyroidectomy

Summary: it has been reported that target-controlled infusion of remifentanil can reduce cough against endotracheal tube during emergence from general anesthesia. we hypothesized that effective concentration of remifentanil for preventing cough during anesthetic emergence varies depending on the type of main anesthetic agents which is administered with remifentanil during general anesthesia. the purpose of this study is to evaluate the effective concentrations of remifentanil to prevent coughing during emergence from general anesthesia according to main anesthetic agent (sevoflurane, desflurane, and propofol).


Eligibility criteria:
inclusion criteria: * aged 20-60 * asa classification i\~ii * female patients * patients who undergoing thyroidectomy exclusion criteria: * patients with acute or chronic respiratory disease * patient who has smoking history * patient who has hypertension * patient who has esophageal reflux * patient who having an expectorant or cough remedy
tolerability and measurability of the efficacy of non pharmaceutical measures to prevent seasonal influenza

Conditions: Influenza

Summary: with this study the investigators will try to assess the tolerability and measurability of the efficacy of non pharmaceutical measures to prevent seasonal influenza in individual households. households with an identified index case of influenza will be randomised into one of three intervention arms: 1. group, where the household will receive general information about transmission of influenza virus and means to prevent it (controls); 2. group, which will receive surgical masks and be asked to wear them whenever they are in close contact with the index case or other persons of the household that became ill during the observation period; 3. group, which will be given and asked to wear surgical masks as well as to execute intensified hand hygiene. in addition to assessing the secondary attack rate as our primary outcome measure, the investigators will also try to evaluate compliance to those interventions by questionnaires.


Eligibility criteria:
inclusion criteria: * influenza like illness symptoms * positive rapid test for influenza * inclusion within 48h of symptom onset * inclusion of at least 3 members of a household (including index case) exclusion criteria: * severe illness * other cases of similar symptoms within 14 days before onset of symptoms in index patient * severe asthma or copd * pregnancy of index

Keywords: non pharmaceutical measures
characterization of immune semaphorin in non alcoholic fatty liver disease and nash

Conditions: Non Alcoholic Fatty Liver Disease

Summary: recent epidemiological studies in france showed a high prevalence of obesity (14.5%) and its strong increase in the last 20 years. among the many complications associated with obesity, liver complications (steatosis and steatohepatitis \[nash\]) are among the most common. semaphorins were described in the early 1990. more than 20 types of these proteins have been reported to date. these proteins were used for neural development. since many functions have also been described. the semaphorins are involved in numerous physiological or physiopathological processes (cardiac morphogenesis, vascular growth, tumor progression), the regulation of immune cells and liver fibrosis. preliminary studies have allowed to show that dendritic cells infiltrate adipose tissue and initiate the activation of t cells and inflammation. immune semaphorin are new players in the regulation of inflammation and immune reactions. the role of immune semaphorin in regulating inflammation in the two compartments (liver and adipose tissue) could be a crucial step that could lead to more severe liver damage. its dysregulation could explain nash injuries. the goal is to identify a new mode of regulation of cellular homeostasis in the fatty liver disease. these factors may serve as diagnostic markers or future therapeutic targets.


Eligibility criteria:
morbid obese patients inclusion criteria: * male and female aged 18-65 years * patients with body mass index justifying a surgery for obesity (bmi ≥ 40 kg / m2 or bmi ≥ 35 kg / m2 with comorbidities) * consumption of alcohol \<20 g / d * patients affiliated to a social security insurance * patients who signed the informed consent exclusion criteria: * hemochromatosis * toxic hepatitis * deficiency of alpha-1-antitrypsin * wilson's disease * liver autoimmune disease (primary biliary cirrhosis, autoimmune hepatitis) * hepatitis b, c * drug-induced hepatitis * presence of hiv status * corticosteroids, amiodarone, valproic acid, tamoxifen, anti-inflammatory drugs, lipid lowering agents, testosterone agonists or beta-adrenergic antagonists, orlistat. * pregnant or breastfeeding women * incarcerated patients or patient under guardianship
clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in hip fracture patients.

Conditions: Hip Fractures

Summary: hip fracture in elderly patients is a pathology with a high economic and health impact on the patient himself and on the national health system, especially considering the significant aging of the population of the basque country. despite advances, hip fracture remains in the clinical groups with the highest in-hospital mortality. hip fracture is associated with numerous adverse events and high mortality. numerous antifibrinolytics, such as tranexamic acid (txa), have been used to limit bleeding in orthopedic surgery and thus prevent the need for blood transfusion. numerous studies have shown that the use of tranexamic acid does not increase the risk of thrombosis. it is proposed to carry out clinical research with drugs without commercial interest. a randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in elderly patients with hip fracture.

prevention and treatment of bleeding due to general or local fibrinolysis

Eligibility criteria:
inclusion criteria: * patients over or equal to 65 years of age, of both sexes, who are going to be operated on for a hip fracture * accept participation in the study (informed consent that will be signed by the patient or family member/legal representative depending on the patient's degree of autonomy). exclusion criteria: * under treatment with another experimental drug (who is not participating in another clinical trial with an experimental drug). * the refusal of the patient or their relatives/legal representative to participate in the study. * known allergy to txa ( hipersensivity to txa o to any of the excipients). * patients with a history of seizures. * patients with severe renal and hepatic insufficiency. * patients with venous thrombosis. * patients with active concomitant bleeding of renal origin.

Keywords: hip fracture blood loss tranexamic acid
prevalence of self-reported premenstrual syndrome and analysis of somatic and psychoemotional symptoms

Conditions: Premenstrual Syndrome

Summary: in brazil there are few published studies that study, the prevalence, symptoms and the population's knowledge about the premenstrual syndrome of women of reproductive age, and that correlate these data with the sociodemographic conditions of these women. in addition, given the complexity of the diagnosis of pms, the prevalence of pms in the brazilian female population may be lower than the self-reported and published in these works, since not all women who believe they suffer from pms fully comply with the criteria contemplated in the consensus for diagnosis of pms. in this sense, this study aims to analyze the prevalence and intensity of frequent symptoms of pms reported by the brazilian female population. the information generated with this study may help to rethink behaviors to improve the health and quality of life of these women, as well as offer tools for decision making related to the need for early and effective treatment of pms, whose disorders are associated with both the fall present and future quality of life for women, as well as all of their family, social and professional coexistence.

in brazil and latin america there are still few published studies that study, the prevalence, symptoms and the population's knowledge about the premenstrual syndrome of women of reproductive age, and that correlate these data with the sociodemographic, socioeconomic and sociocultural conditions of these women . in the investigator's view, this study brings value not only to contribute to the understanding and demystification of pms by society in general, but also for the professionals who assist these women. the data currently used in brazil, and which are frequently used to guide public health policies, are mostly the result of research carried out in other countries, and which may not correspond to the national reality. the information generated with this study may help to rethink behaviors to improve the health and quality of life of these women, at this stage in which comprehensive attention to the health and needs of this population should be given, often providing contraceptive methods that offer, as a benefit relief of symptoms related to pms. the data from this research may also offer tools for decision making related to the need for early and effective treatment of pms, whose disorders are associated with both the decrease in the present and future quality of life for the woman, as well as all of her family life, social and professional.

Eligibility criteria:
inclusion criteria: * data from questionnaires that integrate the anonymous secondary database generated in the period between 20/02/2019 and 03/20/2020, of female participants aged between 20 and 49 years, in which all necessary information has been filled out according to the participant's profile. exclusion criteria: * the present study does not include exclusion criteria
doctor-patient communication in spanish

Conditions: Upper Respiratory Infection; Hypertension; Diabetes

Summary: does use of a translator or use of less than perfect spanish diminish provider-patient communication compared to a native speaker.

spanish speaking drop-in patients will be consented then randomized to receive care by a native spanish speaker, an english speaker using a translator, or an english speaker with intermediate spanish skills using spanish. after the visit, the researcher will enquire about patient satisfaction, when the next appointment is, whether medication has been changed, and what instructions their provider gave them. each provider will do a similar questionnaire. a blinded researcher will score a concordance of plans between provider and patient to see if there is a significant difference in retained information between the groups.

Eligibility criteria:
inclusion criteria: * spanish speaker exclusion criteria: -

Keywords: hispanic communication
preoperative alignment of total knee replacement

Conditions: Knee Arthritis

Summary: the hypothesis of this study is that total knee alignment will be improved by preoperative planning from ct scans and the production of custom instruments compared to the use of standard instruments.

patients will be randomized to have either customized knee instruments or standard generic instrumentation for primary total knee replacement. postoperative ct scan will be used to determine alignment of each group.

Eligibility criteria:
inclusion criteria:patients undergoing primary total knee replacement - exclusion criteria:patients who have hardware involving the hip, knee or ankle -

Keywords: alignment
ozurdex for retinal vein occlusion study (orvo study)

Conditions: Retinal Vein Occlusion

Summary: to measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of ozurdex.

to measure various pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema despite prior treatment with anti-vegf agents at baseline and at 4 weeks after intraocular injection of ozurdex.

Eligibility criteria:
inclusion criteria: * signed informed consent and authorization of use and disclosure of protected health information * age more than or equal to 18 years * diagnosis of macular edema due to central or branch retinal vein occlusion * intraretinal or subretinal fluid in the macula determined by spectralis oct * best corrected visual acuity score in the study eye of 20/30 to 20/400 inclusive (snellen equivalents using the etdrs protocol at a distance of 4 meters) * in the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from vein occlusion and not from other obvious causes of decreased vision * persistent or recurrent edema despite prolonged treatment with an anti-vefg agent exclusion criteria: * scatter laser photocoagulation or macular photocoagulation within 3 months of study entry in the study eye * intraocular surgery in the study eye within 3 months of study entry * use of intraocular or periocular injection of steroids in the study eye (e.g., triamcinolone) within 4 months of study entry * previous use of an anti-vegf drug within 1 month of study entry * yttrium-aluminum-garnet (yag) laser capsulotomy within 1 month of study entry * any condition that the investigator believes would pose a significant hazard to the subject if investigational therapy were initiated. * inability to comply with study or follow up procedures * history of glaucoma or documented history of steroid-induced glaucoma. * patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. * aphakic eyes with rupture of the posterior lens capsule. * eyes with aciol and rupture of the posterior lens capsule. * patients with hypersensitivity to dexamethasone or to any other components of the product